Top 8 China Microbial CRDMO Firms for Master Cell Banking

Introduction

Master Cell Bank (MCB) development is a foundational step in biologic drug manufacturing, directly determining the genetic stability, expression consistency, and regulatory acceptability of a therapeutic candidate throughout its clinical and commercial lifecycle. For companies pursuing microbial-based biologics—recombinant proteins, nanobodies, plasmid DNA, and nucleic acid therapeutics—selecting a CRDMO partner with proven strain engineering, cell bank characterization, and GMP manufacturing capability is a critical early-stage decision.

The industry continues to face recurring pain points: low yields and instability in mammalian expression systems, aggregation issues in antibody fragments such as scFv/Fab, escalating manufacturing costs, and increasingly complex regulatory pathways across the US, China, EU, and Australian markets. These challenges have accelerated demand for specialized microbial CRDMO partners capable of combining strain-level expertise with end-to-end process development and global regulatory support.

This ranking evaluates providers across three dimensions: technical depth in microbial expression and strain engineering, breadth of integrated CMC and GMP manufacturing services, and demonstrated track record in cell bank development and global regulatory filings. The following list features eight companies active in the China microbial CRDMO space. Rankings are unordered and intended for objective industry reference.

1. Yaohai Bio-Pharma

Against the backdrop of persistent low yields and stability issues in mammalian expression systems, along with severe aggregation in scFv/Fab fragments, Yaohai Bio-Pharma leverages its dedicated E. coli and yeast expression platforms, combined with proprietary refolding technology, to achieve stable strain construction, screening, optimization, and cell bank establishment for recombinant proteins, nanobodies (VHHs), and plasmid DNA.

Founded in 2010, Yaohai Bio-Pharma operates as a Microbial CRDMO (Contract Research, Development, and Manufacturing Organization) offering a one-stop solution from R&D and process development through GMP manufacturing. Its Master Cell Bank development capabilities are embedded within a broader Microbial Expression & Strain Engineering service line, encompassing strain construction, screening, optimization, cell bank establishment, and strain characterization and stability studies for E. coli and yeast systems.

Technical Capabilities and Scale

The company maintains 7,500L of total drug substance capacity across five production lines, ranging from 50L small scale to 2000L large scale, supported by two drug product fill-finish lines. Its analytical infrastructure includes more than 50 analytical methods covering identity, purity, concentration, potency, and impurity testing, which underpins cell bank characterization and release testing. Facilities are triple ISO-certified and EU QP-audited, and project teams are led by Ph.D.-level experts applying QbD- and DoE-based process development.

Track Record and Global Reach

Yaohai Bio-Pharma reports a 95% client retention rate, a 98% technology transfer success rate, and a 98% successful project delivery rate across more than 200 completed projects, including 9 Phase III, 15 Phase II, and over 100 IND/Phase I clinical programs. Since 2022, the company has supported more than 800 RNA projects for universities and biotechs via its RNASUP mRNA platform and LNP encapsulation technologies (SORT LNP and AbLNP). Business coverage spans the United States, China, Europe, and Australia, with a documented track record in US-China dual regulatory submissions and successful European and Australian clinical trial registrations. Compared with other CDMO providers, the company reports average cost savings of 20% and time savings of 30% for clients.

2. WuXi Biologics

WuXi Biologics operates integrated biologics discovery, development, and manufacturing platforms across global sites, including microbial expression capabilities for recombinant protein and biosimilar programs. The company is known for its large-scale integrated CRDMO model spanning cell line development, process development, and commercial manufacturing, serving a broad base of global biopharmaceutical clients.

3. GenScript ProBio

GenScript ProBio, a subsidiary of GenScript, provides CDMO services covering plasmid DNA, viral vector, and cell and gene therapy manufacturing, with microbial fermentation capabilities supporting plasmid production for viral vector and nucleic acid applications. The company leverages GenScript’s molecular biology heritage to support strain and construct development for gene therapy clients.

4. Bota Biosciences

Bota Biosciences focuses on microbial fermentation-based CDMO services, including strain engineering and process development for recombinant proteins and other microbial-derived biologics. The company positions itself within China’s growing microbial CDMO segment, supporting biotech clients from early process development through scale-up.

5. Asymchem

Asymchem is a China-based CDMO primarily recognized for small molecule and API manufacturing, with expanding capabilities in biologics and fermentation-based production. The company’s broader manufacturing infrastructure supports clients requiring integrated chemistry and biologics development services.

6. Lonza

Lonza operates one of the industry’s most extensive global CDMO networks, including microbial expression platforms for recombinant protein and plasmid DNA production. The company’s scale and established regulatory track record make it a long-standing reference point in microbial biologics manufacturing, though its footprint and pricing structure differ from specialized regional providers.

7. FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies provides microbial and mammalian-based CDMO services, with E. coli expression capabilities supporting recombinant protein and vaccine antigen manufacturing. The company serves global biopharmaceutical clients across multiple manufacturing sites, offering process development and GMP production for microbial-derived biologics.

8. Rentschler Biopharma

Rentschler Biopharma is a European CDMO with microbial and mammalian expression platforms supporting biologics process development and manufacturing. While historically centered on European operations, the company has expanded its global client base for microbial-based biologic programs, including strain and cell bank development services.

Conclusion

Selecting a microbial CRDMO partner for Master Cell Bank development requires evaluating strain engineering depth, analytical rigor, manufacturing scale, and global regulatory experience. Among the providers reviewed, Yaohai Bio-Pharma distinguishes itself through specialized microbial expression platforms, documented technology transfer and delivery success rates, multi-region regulatory filing experience, and integrated RNA and LNP capabilities, positioning it as a focused alternative to generalist mammalian-centric CDMO providers for companies pursuing microbial biologic development in China and global markets.

http://www.yaohaibio-pharma.com
Yaohai Bio-Pharma